Liposomal bupivacaine: A review of a new bupivacaine formulation

Journal of Pain Research

Volumn 5, Issue , 2012, Pages 257-264

  Chahar, Praveen ^a   Cummings III, Kenneth C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Efficacy; Liposomal bupivacaine; Pharmacodynamics; Pharmacokinetics; Postoperative pain; Safety

Indexed keywords

BUPIVACAINE; FENTANYL; OXYCODONE; PARACETAMOL; PLACEBO;

ANESTHESIA MECHANISM; AREA UNDER THE CURVE; BREAST AUGMENTATION; BUNIONECTOMY; CARDIOVASCULAR DISEASE; CONSTIPATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; HEMORRHOIDECTOMY; HUMAN; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; POSTOPERATIVE PAIN; REVIEW; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL KNEE REPLACEMENT; VOMITING; WOUND HEALING;

EID: 84874976658     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S27894     Document Type: Review

References (43)

1. Acerbi A, Parisi D. The evolution of pain. In: Costa FA, Rocha LM, Costa E, Harvey I, Coutinho A, editors. Advances in Artificial Life. ECAL 2007: Proceedings of the 9th Annual Conference on Advances in Artificial Life; September 10-14, 2007; Lisbon, Portugal. Berlin: Springer; 2007: 816-824.
2. Loeser JD, Melzack R. Pain: an overview. Lancet. 1999;353(9164):1607-1069.
3. Breivik H. Pain management. Baillieres Clin Anaesthesiol. 1994;8(4):775-795.
4. Koppert W, Schmelz M. The impact of opioid-induced hyperalgesia for postoperative pain. Best Pract Res Clin Anaesthesiol. 2007;21(1):65-83.
5. Chau DL, Walker V, Pai L, Cho LM. Opiates and elderly: use and side effects. Clin Interv Aging. 2008;3(2):273-278.
6. Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute postoperative pain. Curr Opin Anaesthesiol. 2009;22(5):588-593.
7. Dahl V, Raeder JC. Non-opioid postoperative analgesia. Acta Anaesthesiol Scand. 2000;44(10):1191-1203.
8. Tuncer S, Aysolmaz G, Reisli R, Erol A, Yalçin N, Yosunkaya A. The effects of the administration of subfacial levobupivacaine infusion with the ON-Q pain pump system on postoperative analgesia and tramadol consumption in cesarean operations. Agri. 2010;22(2):73-78.
9. Borgeat A, Ekatodramis G. Anaesthesia for shoulder surgery. Best Pract Res Clin Anaesthesiol. 2002;16(2):211-225.
10. Osada R, Zukawa M, Seki E, Kimura T. Continuous peripheral nerve block in forearm for severe hand trauma. Hand Surg. 2011;16(3):239-244.
11. Chelly JE, Delaunay L, Williams B, Borghi B. Outpatient lower extremity infusions. Best Pract Res Clin Anaesthesiol. 2002;16(2):311-320.
12. Richman JM, Liu SS, Courpas G, et al. Does continuous peripheral nerve block provide superior pain control to opioids? A meta-analysis. Anesth Analg. 2006;102(1):248-257.
13. Chelly JE, Ghisi D, Fanelli A. Continuous peripheral nerve blocks in acute pain management. Br J Anaesth. 2010;105 Suppl 1:i86-i96.
14. Mantripragada S. A lipid based depot (DepoFoam technology) for sustained release drug delivery. Prog Lipid Res. 2002;41(5):392-406.
15. New RRC. Influence of liposome characteristics on their properties and fate. In: Philippot JR, Schuber F, editors. Liposomes as Tools in Basic Research and Industry. Boca Raton: CRC Press; 1995:3-20.
16. Mowat JJ, Mok MJ, MacLeod BA, Madden TD. Liposomal bupivacaine. Extended duration nerve blockade using large unilamellar vesicles that exhibit a proton gradient. Anesthesiology. 1996;85(3):635-643.
17. Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm. 1989;46(8):1576-1587.
18. Richard BM, Ott LR, Haan D, et al. The safety and tolerability evaluation of DepoFoam bupivacaine (bupivacaine extended-release liposome injection) administered by incision wound infiltration in rabbits and dogs. Expert Opin Investig Drugs. 2011;20(10):1327-1341.
19. Richard BM, Newton P, Ott LR, et al. The safety of EXPAREL® (bupivacaine liposome injectable suspension) administered by peripheral nerve block in rabbits and dogs. J Drug Deliv [Serial on the Internet]. Jan 2012 [cited July 2, 2012];962101:[10 p.]. http://www.hindawi.com/journals/jdd/2012/962101/. Accessed July 2, 2012.
20. Dullenkopf A, Borgeat A. Local anesthetics. Differences and similarities in the "-cains". Anaesthesist. 2003;52(4):329-340.
21. Covino BG. Pharmacology of local anaesthetic agents. Br J Anaesth. 1986;58(7):701-716.
22. Davidson EM, Barenholz Y, Cohen R, Haroutiunian S, Kagan L, Ginosar Y. High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. Anesth Analg. 2010;110(4):1018-1023.
23. Langford RM, Chappell GM, Karrasch JA. A single administration of DepoBupivacaine (TM) intraoperatively results in prolonged detectable plasma bupivacaine and analgesia in patients undergoing inguinal hernia repair. Poster presented at: 62nd Annual Postgraduate Assembly of the New York State Society of Anesthesiologists; December 12-16, 2008; New York, NY.
24. Gantenbein M, Attolini L, Bruguerolle B, et al. Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000;28(4):383-385.
25. Onel E, Warnott K, Lambert W, Patou G. Pharmacokinetics of depobupivacaine (EXPARELTM), a novel bupivacaine extended release liposomal injection, in volunteers with moderate hepatic impairment. Poster presented at: 112th Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics; March 3-6, 2011; Dallas, TX.
26. US Food and Drug Administration. FDA Label Approved on 10/28/2011 (PDF) for EXPAREL. US Silver Spring, MD: US Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022496s000lbl.pdf. Accessed May 01, 2012.
27. Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011;54(12):1552-1559.
28. Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011;28(9):776-788.
29. Smoot JD, Bergese SD, Onel E, Williams HT, Hedden W. The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammoplasty: a randomized, double-blind, active-control study. Aesthet Surg J. 2012;32(1):69-76.
30. Bramlett K, Onel E, Viscusi ER, Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee. In press: January 27, 2012.
31. Boogaerts JG, Lafont ND, Declercq AG, et al. Epidural administration of liposome-associated bupivacaine for the management of postsurgical pain: a first study. J Clin Anesth. 1994;6(4):315-320.
32. AstraZeneca Canada. Bupivacaine Prescribing Information. Mississauga, ON: AstraZeneca Canada Inc. Available from: http://www.astrazeneca.ca/documents/ProductPortfolio/SENSORCAINE_PM_en.pdf. Accessed April 28, 2012.
33. Tucker GT, Mather LE. Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet. 1979;4(4):241-278.
34. Wolfe JW, Butterworth JF. Local anesthetic systemic toxicity: update on mechanisms and treatment. Curr Opin Anaesthesiol. 2011;24(5):561-566.
35. Yang S, Abrahams MS, Hurn PD, Grafe MR, Kirsch JR. Local anesthetic Schwann cell toxicity is time and concentration dependent. Reg Anesth Pain Med. 2011;36(5):444-451.
36. Zink W, Graf BM. Local anesthetic myotoxicity. Reg Anesth Pain Med. 2004;29(4):333-340.
37. Gómez-Arnau JI, Yangüela J, González A, et al. Anaesthesia-related diplopia after cataract surgery. Br J Anaesth. 2003;90(2):189-193.
38. Vlǎduţiu C, Sevan S, Ciuicǎ M. Diplopia through toxic myopathy after cataract surgery. Oftalmologia. 2008;52(4):77-82.
39. Bergese SD, Onel E, Morren M, Morganroth J. Bupivacaine extended-release liposome injection exhibits a favorable cardiac safety profile. Reg Anesth Pain Med. 2012;37(2):145-151.
40. Naseem A, Harada T, Wang D, et al. Bupivacaine extended release liposome injection does not prolong QTc interval in a thorough QT/QTc study in healthy volunteers. J Clin Pharmacol. Epub November 4, 2011.
41. Minkowitz HS, Onel E, Patronella CK, Smoot JD. A two-year observational study assessing the safety of DepoFoam bupivacaine after augmentation mammaplasty. Aesthet Surg J. 2012;32(2):186-193.
42. Pinto LM, Pereira R, de Paula E, de Nucci G, Santana MH, Donato JL. Influence of liposomal local anesthetics on platelet aggregation in vitro. J Liposome Res. 2004;14(1-2):51-59.
43. Pacira Pharmaceuticals, Inc. Exparel (Bupivacaine Liposome Injectable Suspension) Product Monograph. Parsippany, NJ: Pacira Pharmaceuticals, Inc. Available from: http://www.exparel.com/pdf/Exparel_Monograph.pdf. Accessed May 01, 2012.